- Login
- Register & Subscribe
- Language: EN FR DE
Clinical Research
Lilly stops Alzheimer’s disease study
Friday 14 June 2013
Eli Lilly and Company has stopped a Phase 2 study of a beta secretase inhibitor being investigated in Alzheimer’s disease as a result of abnormal liver tests in patients. The decision doesn’t affect other compounds in development, the company said.
Location
United States
AstraZeneca to drop fostamatinib programme
Tuesday 4 June 2013
AstraZeneca Plc has said it will not seek to register fostamatinib, a spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis, following disappointing results from a Phase 3 programme. It will return rights to its partner, Rigel Pharmaceuticals Inc.
Location
United Kingdom
French nuclear medicine company raises €4.8 million
Sunday 26 May 2013
Advanced Accelerator Applications (AAA) SA of France has raised €4.8 million in a placement of its shares with existing and new investors in order to finance an expansion of its manufacturing capacity for radioactive agents for Positron Emission Tomography (PET) imaging. Funds will also be used to investigate a second indication for the company’s radiopharmaceutical for cancer, Lutathera.
Location
France
Wellcome Trust funds cancer prognosis project
Monday 20 May 2013
The Wellcome Trust is allocating £2.7 million to a UK project that will use new gene sequencing technology to identify mutations that predispose patients to cancer and then to integrate this information into routine patient care.
Location
United Kingdom
Galápagos and AbbVie extend JAK1 alliance
Friday 17 May 2013
AbbVie Inc (formerly part of Abbott Laboratories) is expanding its collaboration with Galápagos NV of Belgium to take the Galápagos JAK1 inhibitor, GLPG0634, into Crohn’s disease. The molecule is already being investigated for rheumatoid arthritis.
Location
Belgium
Sanofi reports on JAK2 inhibitor in MF
Friday 17 May 2013
Sanofi SA said that its JAK2 inhibitor for myelofibrosis met its primary endpoint in a Phase 3 pivotal study. The placebo-controlled study was conducted in 24 countries under a Special Protocol Assessment with the US Food and Drug Administration.
Location
France
Tocilizumab shown superior in study: The Lancet
Sunday 5 May 2013
Tocilizumab (Actemra/Roche) has been shown to be superior to adalimumab (Humira/Abbott) in a head-to-head Phase 4 study in patients with rheumatoid arthritis, according to an article in The Lancet on 4 May 2013. The article appeared earlier on-line.
Location
United Kingdom
Merck to help Pfizer test diabetes drug
Tuesday 30 April 2013
In another example of Big Pharma collaboration in the area of diabetes, Merck & Co Inc has announced plans to collaborate with Pfizer in the development and commercialisation of ertugliflozin, a Phase 3-ready diabetes drug in the SGLT2 class.
Location
United States
MorphoSys starts antibody study in ALL
Friday 26 April 2013
MorphoSys AG has initiated a Phase 2 study of its proprietary antibody, MOR208, for patients with B-cell acute lymphoblastic leukaemia. The antibody is one of three in the clinic from the company’s internal portfolio. The study is taking place in the US.
Location
Germany
TiGenix reports on cell therapy trial in RA
Monday 22 April 2013
TiGenix NV has reported that a Phase 2a study of its allogeneic stem cell therapy in patients with refractory rheumatoid arthritis had positive six-month safety data. The trial enrolled patients who had failed to respond to at least two biologic therapies.
Location
Belgium
Select a News Category
Recent Appointments
Steffen Thirstrup joins NDA Group
Monday June 10 2013
Tarquin Bennett-Coles joins Odgers Berndtson
Monday June 10 2013
Sandy Eisen becomes non-executive director at Phosphate Therapeutics
Thursday June 6 2013
Eric-Paul Paques to chair Grünenthal
Thursday June 6 2013
Charles DeCarli joins advisory board at DiaGenic
Thursday June 6 2013